BioHarvest Sciences (DE:8MV0)
FRANKFURT:8MV0
8MV0 Stock Chart & Stats
€10.80
-€0.05(-0.86%)
At close: 4:00 PM EST
€10.80
-€0.05(-0.86%)
Day’s Range― - ―
52-Week Range€2.44 - €10.80
Previous CloseN/A
Volume0.00
Average Volume (3M)454.00
Market Cap
€64.48M
Enterprise Value€54.08M
Total Cash (Recent Filing)€19.17M
Total Debt (Recent Filing)€16.42M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 31, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding22,667,843
10 Day Avg. Volume946
30 Day Avg. Volume454
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.36Price Target Upside-4.10% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)€37.02M
Bulls Say, Bears Say
Bulls Say
Revenue & MarginsSustained top-line growth to roughly $35M TTM with materially improved gross margins (~59%) indicates durable unit economics across product and ingredient lines. Strong margins provide room to invest in D2C marketing and CDMO scale while improving the path to operating leverage and eventual profitability.
CDMO Contracts & RoyaltiesSecuring multi-stage CDMO deals with retained ownership (20% on a $1.2M Stage‑2 fragrance program) shifts the business toward royalty and composition‑ownership economics. This builds recurring, higher-margin upside versus pure services and strengthens long-term differentiation in high-value botanicals.
D2C Brand TractionVINIA’s large active user base and successful product launches (Blood Flow Hydration ~ $1M sales and high ratings) show durable consumer adoption and brand equity. A repeatable D2C engine supports predictable revenue, higher gross margins and cross-sell, improving sustainable cash generation prospects if retention holds.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the company relies on external financing to fund growth and operations. Continued cash burn constrains strategic flexibility, raises dilution or debt risks, and could delay capacity or commercialization plans if revenue inflection or margin gains slip.
Ongoing Net LossesMaterial and recurring net losses depress returns on equity and indicate profitability remains distant. Without consistent operating income improvements, management may need to curb spending or raise capital, both of which can undermine execution of the dual CDMO/D2C strategy and shareholder value over the medium term.
Execution & Capacity RiskScaling CDMO and commercializing saffron/fragrance programs depends on a new facility slated for H2 2027. Delays, construction problems or funding shortfalls would bottleneck production, defer royalty and manufacturing revenue, and magnify execution risk tied to multi-quarter commercialization timelines.
BioHarvest Sciences News
8MV0 FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was €2.44 and its highest was €10.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is €64.48M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Aug 31, 2026 which is in 73 days.
How were BioHarvest Sciences’s earnings last quarter?
Currently, no data Available
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Overvalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.1.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in DE:8MV0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.36 (-4.10% Downside)
€10.36 (-4.10% Downside)
Blogger Sentiment
Neutral
DE:8MV0 Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.22%
12-Months-Change
Fundamentals
Return on Equity
-88.01%
Trailing 12-Months
Asset Growth
71.33%
Trailing 12-Months
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.
8MV0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid technological and commercial progress — notable CDMO milestones (Stage 1 completions, a $1.2M Stage 2 fragrance contract with 20% retained ownership, and Saffron Stage 1 advancement), stronger cash position, and clear D2C product traction (VINIA Blood Flow Hydration, strong reviews, active users). However, near-term financials show continued net losses, increased operating and marketing spend, and a deliberate D2C marketing reset that temporarily depressed revenue. Execution risks remain around manufacturing capacity timing (new facility target H2 2027), potential future capital needs, and early-stage validation for novel assets. Overall the positives (milestones, cash build, pipeline, product traction and reiterated guidance) outweigh the short-term headwinds and uncertainties, but successful execution over the next quarters — especially H2 2026–2027 — will be critical to realize the opportunities.View all DE:8MV0 earnings summaries8MV0 Stock 12 Month Forecast
Average Price Target
€10.36
▼(-4.10% Downside)
Technical Analysis
Options Prices
Currently, No data available
---